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1. Introduction 
Furchgott and his co-workers reported the vascular actions of an unknown biological 
mediator that was named endothelium-derived relaxing factor (EDRF).1 Nitric oxide (NO) 
was soon discovered as a vasodilator that had identical properties with EDRF.2,3,4 NO 
produced by the endothelium diffuses to the adjacent vascular smooth muscle cells causing 
them to relax. This function is important in many vascular beds such as the coronary 
circulation.5, 6  
Nitric oxide synthases produce nitric oxide. In the endothelium, constitutive endothelial 
nitric oxide synthase (eNOS) produces nitric oxide (NO) under normal conditions and in 
response to chemical and physical stimuli such as shear stress. 6, 7, 8, 9 NO produced from 
endothelial cells or from platelets serves protective functions such as inhibiting platelet 
aggregation and adhesion and inhibiting leukocyte adhesion.10, 11 Nitric oxide produced by 
constitutive neuronal nitric oxide synthase (nNOS) is a neuromediator in the central nervous 
system12, 13 and in peripheral non adrenergic-non cholinergic nerves14, 15, 16 where is mediates 
many physiological functions.  
The second messenger or “molecular receptor” activated by NO to mediate these 
physiologic functions is soluble guanylate cyclase (GC).17, 18 In the vasculature, this pathway 
has been clearly outlined to involve intracellular increase in the concentration of cyclic 
guanosine monophosphate (cGMP),19, 20 activation of protein kinase G (PKG, cyclic GMP-
dependent protein kinase),21 and modulation of activities of cyclic nucleotide 
phosphodiesterases (PDE, 2, 3, and 5). In vascular smooth muscle cells the net effect is 
decreased phosphorylation of the myosin light chain, reduction of cytosolic Ca,2+ and 
relaxation of smooth muscle cells. PKG plays a key role in vasodilation. PKG catalyzes the 
phosphorylation of certain proteins. It also activates myosin light chain phosphatase22 
causing dephosphorylation of mysosin light chain and vasorelaxation. 
A third isoform of the enzyme is inducible nitric oxide synthase (iNOS) which is induced by 
immunologic stimuli and activated in pathologic conditions. It produces cytotoxic amounts 
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of NO for host defense. 23, 24, 25, 26 All three terms: endothelial, neuronal, and inducible are 
traditional and presently exceptions have been identified in the variety of NOS enzymes. 
Many cardiovascular diseases and pathologic conditions are related to abnormalities and 
irregularities of the NOS function and NO signaling. For example nNOS overproduction of 
NO is involved in some forms of epilepsy and iNOS overproduction of NO causes septic 
shock. Chronic diseases linked to deranged NO production include atherosclerosis, 
hypertension, cerebral and coronary vasospasm, and erectile dysfunction. Therefore, NO 
delivery and NO control are therapeutic targets.27, 28, 29 Inhaled NO is especially useful for 
neonates with persistent pulmonary hypertension.30,31  Nitric oxide donors are drugs used to 
enhance or substitute NO availability. They include organic nitrates and nitrites and have 
been used to lower blood pressure and for ischemic heart disease. Control of endogenous 
production of NO is dependent on our knowledge of the enzyme, NOS, that produces NO. 
Many chemicals have been used to compete with the amino acid L-arginine substrate from 
which NOS synthesizes NO. Some are experimental tools used to study NOS function, e.g. 
asymmetric dimethyl-l-arginine. NOS inhibitors may be useful in septic shock and 
neurodegenerative diseases.6 However, we know very little about the life cycle of the 
enzyme nitric oxide synthase and how it is physiologically regulated: synthesized, 
deactivated, recycled or replenished in basal conditions in normal endothelial cells. Our 
recent findings of the relationship between protein kinase G and endothelial nitric oxide 
synthase open new thoughts on the regulation of nitric oxide synthase. These findings are 
discussed in this chapter. 
2. Protein kinase G isoforms and their distribution in endothelial cells 
Protein kinase G (PKG) is a serine/threonine-specific protein kinase. It is found in vascular 
smooth muscle cells (SMCs) and there it mediates the effect of endothelial NO on vascular 
SMCs to cause relaxation. Recently, we showed the abundance of PKG in quiescent ovine 
neonatal lung microvascular endothelial cells (LMVECs) and investigations were carried out 
to find out if NO within endothelial cells mediates any physiological function through 
endothelial PKG. A feed-back role of endothelial PKG on activated endothelial NOS appears 
to be a physiologic regulation of NO production.  
PKG is likely to have an important physiologic role in endothelial cells because PKG 
isoforms are present in normal endothelial cells in distinct patterns of distribution (Figure 
1).32 
3. Physical intracellular relationship of NOS and PKG: Colocalization of PKG 
1 beta and serine-116-phosphorylated endothelial nitric oxide synthase  
Recently, using specific epitope fluorescent immunolabeling of monolayers and confocal 
microscopy, NOS was shown to colocalize with PKG in neonatal ovine LMVECs.32 The 
confocal imaging of colocalized serine-116-phosphorylated NOS with PKG 1 beta in 
quiescent MVECs indicated a spatial relationship between the two molecules in intracellular 
domains (Figure 2). Thus we suspect a role for PKG (1 beta) in normal NOS metabolism in 
endothelial cells. 
Till present, the importance of PKG in endothelial NO signaling has been focused on smooth 
muscle cell PKG. NO produced by the endothelium freely diffuses across biological  
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Fig. 1. Fluorescence immunohistochemistry expression of characteristic endothelial markers 
and some protein kinase G (PKG) isoforms in primary cultures of lamb lung microvascular 
endothelial cells (LMVECs). The figure shows newborn lamb (all left panels) and term fetal 
cells (right panel). The upper left panels show 100% of cells in the monolayer stained for 
both von Willebrand Factor (vWF; red alexa 568 staining) and cluster differentiating type 
antigen 31 (CD31, green alexa 488 staining), characterizing them as endothelial cells. The 
lower left panels show alexa 488-conjugated secondary antibodies attached to respective 
primary antibodies. The PKG carboxy terminal is expressed in the cytosol and more 
intensely in the perinuclear region of LMVEC; PKG 1 staining is localized to the Golgi and 
endoplasmic reticulum regions of the cells; and PKG 1 staining is localized to vesicular 
structures distributed all over the cell. 
membranes and stimulates soluble guanylate cyclase in smooth muscle cells leading to 
increased intracellular cGMP, activation of PKG, and smooth muscle cell relaxation. The rest 
of the evidence in this chapter presents an emerging role of an equivalent NO-cyclic GMP-
PKG signaling pathway in the endothelial cell that appears to produce a negative regulation 
of NOS (possibly in addition to endothelial relaxation). 
4. Effects of protein kinase G modulator drugs on endothelial intracellular 
nitric oxide production  
Basal levels of NO production have been difficult to determine because NO has a very short 
half-life of 5s and stimulated NO release is only about 500±20 nmol/s.33 Many previous 
studies have measured stimulated NO production using agonists such as carbachol and 
calcium ionophore and these investigations studied factors altering such NOS function. The 
experimental tool, diaminofluorescein with a difluoro modification (DAF-FM) forms a 
relatively photo-stable, water soluble adduct, a fluorescent benzotriazole, with NO34 at 
concentrations as low as 3 nM and can trap NO as it is produced. Importantly, low doses of 
DAF can pick up minute differences between groups with minimal diaminofluorescein 
(DAF) autofluorescence.35, 36 The more important novelty about DAF is probably the 
opportunity it affords us to measure and monitor basal NO as it is produced by living cells. 
DAF is thus an interesting tool for studying basal NOS function 37 which we need to 
understand in order to better regulate nitric oxide production therapeutically. We detected  
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Fig. 2. PKG1beta and serine-116-phosphorylated NOS moieties colocalize in the cytosol and 
nuclear region vesicles. Quadruplet monolayers of untreated passage 3 neonatal ovine lung 
microvascular endothelial cells were fixed with 4% paraformaldehyde, permeabilized with 
0.2 % triton X-100, blocked with 20% bovine serum albumin and then incubated with 1: 200 
dilutions of goat anti PKG 1beta and rabbit anti serine116-phosphorylated NOS primary 
antibodies for 2h at room temperature. They were counterstained with 1: 125 dilutions of 
alexa 488-conjugated donkey anti goat and cy-3 conjugated F(ab)2 fragment specific sheep 
anti-rabbit secondary antibodies. Pictures were taken with a Leica DMIRE2 confocal 
inverted microscope and Leica v2.61 confocal software. The PKG 1beta and pSer116-NOS 
markers colocalized in the cytosol and intensely in vesicles in the nuclear region. 
nitric oxide produced by isolated LMVECs under basal conditions by DAF fluorescence and 
it was inhibited by general NOS inhibitors NG-nitro-L-arginine (L-NNA) or N-nitro-L-
arginine methyl ester (L-NAME). Here we summarize a number of published experiments 
that show that PKG activation negatively regulates activated NOS.32, 38, 39, 40, 41 
Effects of PKG activation on real time basal and stimulated NO production are shown in 
Figure 3 and a dose dependency of the inhibitory effect of PKG on basal NO production is 
shown in Figure 4. The inhibitory effect doubled from 20 nM to 2 micromolar 8-bromo cyclic 
guanosine monophosphate (8-Br-cGMP) in Figure 4 indicating that this inhibitory 
mechanism is sensitive to low physiological levels of 8-Br-cGMP. The inhibition of NOS 
activity by 8-Br-cGMP was prevented by the peptide YGRKKRRQRRRPPLRKKKKKH 
(DT2), a potent PKG inhibitor, indicating that 8-Br-cGMP inhibits NOS through PKG (Figure 
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4). To make such observations, it was necessary to first subtract the large proportion of 
extraneous fluorescence. Basal NO production is at a very low level compared to stimulated 
production (Figure 3). The expansion of the fluorescence axis by extraneous fluorescence can 
minimize or obliterate observation of the effect of drugs on basal NOS activity.  
NOS activity can be activated by such stimuli as cholinergic receptor agonists, shear stress, 
bradykinin receptor agonists, and calcium ionophore.42, 43 Previously, factors modulating 
NOS were studied largely by investigating stimulated NOS activity, NOS activity in vitro 
and in transfection-modified cells using mainly the citrulline assay. Such activation and the 
interaction of NOS and its binding partners may be modulated by proteins such as heat 
shock protein 90 (HSP90),44 nitric oxide synthase traffic inducer (NOSTRIN),45 and eNOS 
interacting protein (NOSIP),46 as well as kinase action by Akt (protein kinase B, PKB) and 
PKA (protein kinase A).47 Basal endothelial nitric oxide production has been difficult to 
measure and study with the citrulline assay. The sensitivity and ease of DAF48 is a valuable 
tool that has enabled us to study more closely this narrow but important margin of 
biological activity (Figure 3). Possibly, derangement of basal NOS activity rather than 
alteration of factors involved in potentiated NOS activity may be the underlying factor in 
some NOS-related vascular diseases because pathology is often a sustained deviation from 
the basal or balanced state.  
The data showing a physiological inhibitory role of PKG on basal NOS activity may be of 
clinical significance. The importance of this is not clear but it seems that activated 
endothelial NOS is not turned off until endothelial PKG is activated, thus ensuring a 
relationship between endothelial NO generation and corresponding vascular smooth muscle 
PKG function. In Figure 5 the effects of various PKG activator and inhibitor drugs also show 
that nitric oxide production in endothelial cells may be negatively regulated by protein 
kinase G feedback. In Figure 6 and Figure 7, the use of NOS inhibition shows that the 
protein kinase G effect appears to be specifically on nitric oxide synthase function. 
Lack of basal PKG activity produced by the antagonist, guanosine-3’, 5’-cyclic 
monophosphorothionate 8-bromo Rp isomer, increases basal NOS activity and the effect of 
the cGMP antagonist is inhibited by NOS inhibitor L-NNA (Figure 6). In Figure 6, after the 5 
min time point, the effect of the competitive inhibitor of NOS, LNNA becomes equilibrated 
and the PKG inhibition can be seen to sustain a cumulative active pool of NOS. 
In another experiment using an extended time-course of up to 360 min, L-NNA also 
enhanced the effect of PKG activator 8-Br-cGMP but reversed the effect of another PKG 
inhibitor Rp-8-Br-PET-cGMPS on NOS function (Figure 7). The graphs obtained had 
correlation values of R2 > 0.9 showing a real relationship between fluorescence changes and 
time of reaction with drugs. The slopes of the graphs all fall within a narrow range of 7.5 – 
8.19 showing lack of variation and indicating parallel shifts. This suggests a molecular 
relationship between NOS and PKG modulators based on receptor activity.  
These results suggest that the effects of PKG are directly on active NOS function. In 
summary, basal (and activated) NOS activity is regulated by the downstream activation of 
PKG by NO-stimulated cGMP production in endothelial cells. It appears that when NOS is 
activated, the NO produced diffuses to the smooth muscle but some of the NO triggers an 
endothelial PKG sensitive signaling that results in inhibition of the activated NOS within the 
endothelial cell. 
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Fig. 3.38 Exogenously administered 8-Br-cGMP attenuates stimulated nitric oxide synthase 
function in ovine LMVECs. Confluent monolayers of sibling cells of passage 4 were used. A 
set of 12 wells with no cells was used to measure DAF autofluorescence in the reaction 
mixture over the time-course of the experiment. To determine the level of extraneous 
fluorescence in the experimental groups, a group of 12 microcultures were treated with NOS 
inhibitor 2 mM L-NAME 1 h before DAF. In all the other groups, drugs (100 microM acetyl 
choline or 100 microM carbachol followed by 1 mM 8-Br-cGMP) were administered just 
before a mixture of 1 microM DAF FM and 2.4 microM DAF-FM diacetate. The basal NO 
group received only the fluorophore. Cells were measured at intervals, starting at 15 min 
after DAF, for total NO (in intracellular and cell bathing medium) that combined with DAF 
to produce fluorescence. All graphs shown are from means of raw fluorescence ± SE of 8 or 
more microcultures per point from a single experiment. Figure shows a representative of 2 
similar experiments. 8-Br-cGMP antagonized the stimulating effects of both acetylcholine 
and carbachol on nitric oxide production. 
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Fig. 4.38 Exogenously administered 8-Br-cGMP attenuates basal nitric oxide synthase 
function in ovine LMVECs. Confluent monolayers of sibling cells of passage 2 were used in 
96 well clusters. They were treated with NOS inhibitor 2.4 mM L-NAME to determine the 
level of extraneous fluorescence in the experimental groups, with 20 nM – 2 microM 8-Br-
cGMP to observe its effect on basal nitric oxide production, with PKG inhibitor 100 ng/ml 
DT2 to determine if 8-Br-cGMP acts through PKG. DT2 or L-NAME were administered 1 h 
before DAF. 8-Br-cGMP was administered 5 min before DAF. A mixture of 0.5 microM DAF 
FM and 0.8 microM DAF-FM diacetate was used to measure the NO in the cell bathing 
medium and intracellular NO together. The basal NO group received only the fluorophore. 
All graphs shown are from means of corrected fluorescence ± SE of 8 or 12 microcultures per 
point from a single experiment. Final fluorescence measurements are raw means minus 
corresponding means of DAF autofluorescence. The figure is a representative of 3 
experiments. 
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Fig. 5.39 Timecourse of the inhibition of nitric oxide production by protein kinase G: 
modifications by PKG inhibitor and activator drugs. Nitric oxide measurements were done 
using 4,5-diamino-fluorescein derivative, DAF-FM, (0.5 ǍM DAF-FM and 0.8 ǍM DAF FM 
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diacetate) added to stably confluent microcultures of LMVECs in 96-well clusters. To show 
the basic effect of PKG activation, cells were incubated with 100 ǍM 8-Br-cGMP. Other 
experimental groups were preincubated with a modulator drug: PKG inhibitors 100 ǍM Rp-
8-Br-PET-cGMPS or 50 nM guanosine 3’-5’-cyclic mono-phosphoro thionate-8-Br-Rp isomer 
Na salt; cGMP inhibitor: 4 ǍM Rp-8-pCPTcGMPS; or PKG activator: 100 ǍM guanosine-3’-5’-
cyclic monophosphate-ǃ-phenyl-1NF-ethano-8-bromo sodium salt. Inhibitors were added 30 
min before DAF and activators were added with DAF. Total NO produced after 5, 90, 180 
and 270 min of incubation with DAF at 37 °C was measured using a Victor 1420 multilabel 
counter (Waltham, Massachusetts) with a fluorescein setting (ǌex/em 485/535 nm). Using 
the 90 min time point, the data plotted as mean ± SE show that 8-Br-cGMP reduces NO 
production in controls and in all the tests with cGMP/PKG inhibitor drugs as well as in tests 
with the PKG activator (p<0.05# in all cases). The cGMP/PKG inhibitor drugs (A), (B) and 
(C) significantly increased NO production (p<0.05* in all cases) and the PKG activator 
guanosine-3’-5’-cyclic monophosphate-ǃ-phenyl-1NF-ethano-8-bromo sodium salt (D) 
significantly decreased NO production (p<0.05+) (lower figure). 
 
Fig. 6.38 Basal nitric oxide production in ovine LMVECs is enhanced by lack of basal 
endothelial PKG activity and this effect is attenuated by nitric oxide synthase inhibitor 
LNNA. Confluent monolayers of sibling cells of passage 4 were used in groups of N=12 for 
basal and N=6 for test groups of microcultures. Cells were treated with different 
concentrations of cGMP antagonist guanosine-3’, 5’-cyclic monophosphorothionate 8-bromo 
Rp isomer (for PKG inhibition) added 30 min before DAF or with the same concentrations of 
the cGMP antagonist plus 125 nM L-NNA previously added 2h before DAF. A mixture of 
0.5 microM DAF FM and 1 microM DAF-FM diacetate was used to measure total 
intracellular and cell bathing medium NO that combined with DAF to produce fluorescence. 
Measurements were made 15 min after DAF was applied. The arrow shows the level of 
basal NO at 15 min in an identical third group not treated with drugs. All graphs shown are 
from means ± SE. Figure shows a representative of 2 similar experiments. The PKG 
inhibition dose-dependently increased NO measured. The inhibition of this effect by L-NNA 
shows it is through NOS. 
www.intechopen.com
 Advances in Protein Kinases 
 
160 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
0 100 200 300 400
TIME (MINS)
D
A
F 
FL
U
O
RE
SC
EN
CE
 
A
T 
 4
85
/5
35
 N
M
BASAL,                                        
SLOPE =7.5075, R2 = 0.9824
6 mM L-NNA,                              
SLOPE = 8.1422, R2 = 0.9799
25 uM 8-Br-cGMP,                       
SLOPE = 8.0396, R2 = 0.9866
A
0
500
1000
1500
2000
2500
3000
3500
4000
4500
0 100 200 300 400
TIME (MINS)
D
A
F 
FL
U
O
RE
SC
EN
CE
 
A
T 
48
5/
53
5 
N
M
BASAL,                                           
SLOPE = 7.5075, R2 = 0.9824
25 uM 8-Br-cGMP,                        
SLOPE = 8.0396, R2 = 0.9866
25 uM 8-Br-cGMP+6 mM L-NNA,
SLOPE = 8.1913, R2 = 0.9539
B
0
500
1000
1500
2000
2500
3000
3500
4000
4500
0 100 200 300 400
TIME (MINS)
D
A
F 
FL
U
O
RE
SC
EN
CE
 
A
T 
 4
85
/5
35
 N
M
BASAL,                                                   
SLOPE = 7.5075, R2 = 0.9824
25 uM Rp-PET-8-Br-cGMPS,                  
SLOPE = 7.8979, R2 = 0.9906
25 uM Rp-PET-8-Br-cGMPS+6 mM
LNNA, SLOPE = 7.4236, R2 = 0.9846
C
 
Fig. 7.38 Specificity of PKG effects on NOS function: NOS inhibitor LNNA enhances the 
effect of PKG activator 8-Br-cGMP on NOS function and reverses the effect of PKG inhibitor 
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Rp-8-Br-PET-cGMPS on NOS function. Confluent monolayers of sibling cells of passage 4 
were used. Inhibitors, 6 mM L-NNA and 25 microM Rp-8-Br-PET-cGMPS were 
administered 2h and 1h respectively before DAF and the PKG activator, 25 microM 8-Br-
cGMP < 5 min before DAF. A mixture of 0.5 microM DAF FM and 0.8 microM DAF-FM 
diacetate was used to measure total intracellular and cell bathing medium NO that 
combined with DAF to produce fluorescence. All graphs shown are means ± SE of 12 for 
basal and 6 for tests microcultures per point. Figure shows a representative of 2 similar 
experiments. A: Inhibition by L-NNA or 8-Br-cGMP produced a parallel shift of the basal 
NOS activity graph downwards. B: Synergy of the effects of L-NNA and 8-Br-cGMP co-
administered.   C: The effect of PKG inhibition produces a parallel shift of basal NOS 
activity graph upwards and this shift is antagonized by L-NNA. 
5. Relationship of PKG activation and phosphorylation of NOS at various 
sites 
Constitutive nitric oxide synthase in endothelial cells is localized to caveolae 49, 50 where it 
docks into the intracellular domain 4 of the bradykinin B2 receptor.51 The structural protein 
of caveolae, caveolin-1, also binds to NOS keeping it inactive52 Activation of NOS leading to 
its dissociation from the complex is calcium dependent.9, 52  A further activation on serine 
1177/1179 is produced by kinase activity.42 Several kinases are known to phosphorylate 
NOS,53 regulating its activity negatively or positively under experimental conditions. Apart 
from constitutive caveolin-1, other negative regulators of NOS are NOSIP54 and NOSTRIN.55 
Both interfere with the association of NOS with caveolae and cause its redistribution from 
the plasma membrane to intercellular compartments with a decrease in nitric oxide (NO) 
production. 
Three positive regulators of NOS have been identified. The protein kinase AKt (PKB) 
phosphorylates NOS on serine 1177/1179, enhancing NOS activation.56 Protein kinase A 
also phosphorylates NOS to increase its activity.47 HSP90 is a molecular scaffold that 
facilitates the interaction of kinases and substrates including NOS. It facilitates the 
dissociation of NOS from caveolae in response to calcium-calmodulin.44, 57 An emerging role 
of protein kinase G in NOS regulation is interesting because not only is it a regular 
downstream component of the physiologic NO signaling pathway that could give feedback 
regulation, but also because experimentally, its involvement in NOS phosphorylation can be 
related to its regulation of NOS function. Presently, PKG is unnoticed as a physiological 
regulator of NOS.58 
We recently published fluorescence activated cell sorter (FACS) analysis of the relationship  
between PKG and endothelial NOS (Figures 8-10).39 In summary, 5 microM 8-Br-cGMP in <5 
min caused an increase in N-terminal labeling of NOS and a decrease in both C-terminal 
and serine 1177 labeling of NOS. 8-Br-cGMP appeared to increase PKG 1 and to decrease 
PKG 1 labeling. Changes in other phosphorylation sites were less consistent but overall 
mean channel fluorescence increased from 19.92 to 217.36 for serine 116 and decreased from 
329.27 to 254.03 for threonine 495 phosphorylation. Data indicated that PKG caused both 
molecular and phosphorylation changes in NOS. Thus an implicated role of PKG and serine 
116 phosphorylation site on NOS may be a future focus for studying the termination of 
activated NOS function and the vesicular processing of the spent enzyme. Several evidences 
from confocal microscopy further develop this.  
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Fig. 8.39 Schema of experimental protocol for fluorescence activated cell sorter analysis of the 
effect of cGMP on antibody labeling of NOS regions and protein kinase G isoforms. Sibling 
cells were pooled and equally distributed for controls and tests. 
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Fig. 9.39 Effect of PKG activation on percentage of cells with high fluorescence intensity for 
various immunolabeling. Cell suspensions in phosphate buffered saline (PBS) containing 5% 
antibiotic/antimycotic mixture were split equally into control and 5 ǍM 8-Br-cGMP 
treatment groups before fixation with 4% paraformaldehyde. Cell were permeabilized with 
methanol, blocked with 20 mg/ml bovine serum albumin (BSA) and then labeled with 1: 100 
primary antibodies against NOS N-terminus, NOS C-terminus, or serine 1177, serine 116, or 
threonine 495 phosphorylated NOS for 2h. They were counterlabelled with FITC conjugated 
secondary antibodies and ran through a BD FACSCallibur. Cells with positive signal of 
fluorescence were analysed using a FITC (fluorescein) filter (FL1). Upper figure shows 
gating of cells for 10 fluorescence units (y-axis) and 10 forward scatter units (x-axis). Middle 
table shows actual Cell Quest read out values for % gated. The mean values of the three de-
terminations were plotted in the lower figure. 
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Fig. 10.39 A. FACS analysis of the effect of PKG activation on NOS N-terminal and C-
terminal specific rabbit antibody labeling and pSer1177 NOS specific antibody labeling. 
Cells were immunolabeled as described for Figure 9. The fluorescence intensities of sample 
populations were captured with a Cell Quest software. Upper channels show control cells 
and lower channels show PKG activator 5 ǍM 8-Br-cGMP treated cells. Left panels were 
labeled with a rabbit anti N-terminal of NOS antibody. Middle panels were labeled with a 
rabbit anti C-terminus of NOS antibody. Right panels were labeled with a rabbit anti serine 
1177 phosphorylated NOS antibody. The fluorescence intensity range (y-axis) was increased 
by PKG activation for N-terminal labeling and decreased by PKG activation for C-terminal 
labeling. The fluorescence intensity range was decreased by PKG activation for serine 1177 
phosphorylation. B. FACS analysis of the effect of PKG activation on antibody labeling of 
protein kinase G isoforms. Upper channels show control cells and lower channels show PKG 
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activator 5 ǍM 8-BrcGMP treated cells. Left panels were labeled with a goat anti PKG 1ǂ 
antibody. Right panels were labeled with a goat anti PKG 1ǃ antibody. PKG activation 
increased total number of cells with >101 fluorescence units (FU) (y-axis) labeling for PKG 
1ǂ and decreased the same labeling for PKG 1ǃ. 
6. PKG phosphorylated nitric oxide synthase in endothelial cells 
The colocalization of serine 116-phosphorylated NOS with PKG suggests that PKG 
phosphorylates NOS at serine 116 but this has not been directly demonstrated. If this is true, 
serine 116 phosphorylation of NOS may be connected with the process of terminating the action 
of NOS after synthesizing NO. The functional data showing modulation of NO production by 
cGMP and the FACS data showing the effect of cGMP on C- and N-terminal expressions of NOS 
and phosphorylation expressions of NOS add up to suggest that serine-116 phosphorylated NOS 
is a spent form of the enzyme. Figure 11 from our published data32, 41 indicates that serine116-
phosphorylated NOS is not like nascent NOS that is known to be associated with the 
plasmalemma and golgi. Serine 116 phosphorylated NOS is found in the cytosol and in 
endoplasmic reticulum (ER) and nuclear site vesicles. Figure 1241 clearly shows that this form of 
NOS is not associated with the plasma membrane. On the other hand, unphosphorylated NOS 
colocalizes with caveolin in the plasmalemma and in the Golgi (Figure 13).41 
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Fig. 11. Serine 116-phosphorylated NOS is found in vesicular structures in endothelial cell 
endoplasmic reticulum and nuclear regions. Triple monolayers of untreated passage 3 
neonatal ovine lung microvascular endothelial cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.2% triton X-100, blocked with 20% bovine serum albumin and then 
incubated with mouse anti protein disulfide isomerase (1: 200) (an endoplasmic reticulum 
(ER)-specific marker) and rabbit anti serine116-phosphorylated NOS (1: 200) primary 
antibodies for 2h at room temperature. They were counterstained with 1: 125 dilutions of 
F(ab)2 fragment specific sheep anti mouse conjugated to green fluorescein isothiocyanate 
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(FITC) and sheep anti rabbit conjugated to red cy-3 secondary antibodies. Pictures were 
taken with a DMIRE2 confocal inverted microscope and Leica v2.61 confocal software. Insert 
shows that a serine 116 phosphorylated NOS moiety passes through the ER and nuclear 
regions of quiescent cells in certain processing vesicles indicating a NOS metabolic pathway. 
 
Fig. 12. Plasmalemma associated tyrosine14-phosphorylated caveolin-1 and serine 116-
phosphorylated NOS are differentially located in endothelial cells. Triple monolayers of 
untreated passage 2 neonatal ovine lung microvascular endothelial cells were fixed with 4% 
paraformaldehyde, permeabilized with 0.2% triton X-100, blocked with 20% bovine serum 
albumin and then incubated with mouse anti tyrosine14-phosphorylated caveolin-1 (1: 200) 
and rabbit anti serine116-phosphorylated NOS (1: 200) primary antibodies for 2h at room 
temperature. They were counterstained with 1: 125 dilutions of F(ab’)2 fragment specific 
goat secondary antibodies against mouse conjugated to green alexa 488 and against rabbit 
conjugated to red alexa 594. Pictures of a field representative of all three monolayers are 
shown taken with a DMIRE2 confocal inverted microscope and Leica v2.61 confocal 
software. Upper panel shows separation of pY14-caveolin-1 marker distinctively in plasma 
membrane and pSer116-NOS marker distinctively in the cytosol and nuclear region. Insert 
from upper panel shown in lower panel depicts the intense distribution of the pSer116-NOS 
moiety in nuclear region vesicles. 
Caveolin-1 is a regulator of NOS that has been well studied. From published work, 
immunoprecipitation of NOS from bovine lung microvascular endothelial cells resulted in 
co-precipitation of caveolin-1.49 Caveolin-1 is well known to be abundant in the membrane 
region.59,60 The binding of caveolin-1 to NOS has been shown to negatively regulate NOS 
activity. 51,52 NOS is bound to caveolin-1 before being activated by extracellular signals and 
PKG does not appear to be involved in such inhibition of NOS at the plasma membrane. In 
the evidence presented here, PKG activation decreases the immunodetection of serine 1177 
phosphorylated moiety of NOS showing that it may be involved in deactivation of activated 
NOS (Figure 14). 
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Fig. 13. Caveolin-1 and endothelial NOS (NOS-3) colocalize in the plasmalemma and Golgi 
in untreated endothelial cells. Triple monolayers of passage 2 neonatal ovine lung 
microvascular endothelial cells were fixed with 4% paraformaldehyde, permeabilized with 
0.2% triton X-100, blocked with 20% bovine serum albumin and then incubated with affinity 
purified rabbit anti caveolin-1 (1: 200) and monoclonal anti NOS(1: 200) primary antibodies 
overnight at 4C. They were counterstained with 1: 125 dilutions of F(ab’)2 fragment specific 
goat secondary antibodies against rabbit conjugated to red alexa 594 and against mouse 
conjugated to green alexa 488. Pictures were taken with a DMIRE2 confocal inverted 
microscope and Leica v2.61 confocal software. Arrows show areas of caveolin-1 and NOS 
co-localization seen in random fields from two monolayers (A and B i) with en-largement of 
some membrane portion of B to show numerous minute membranous colocalization foci 
(yellow, B ii) (scale shows 10 micro meters). 
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Fig. 14.39 A: PKG activation decreases pSer1177-NOS immunofluorescence. To quantitatively 
determine the effect of PKG activation on pSer1177-NOS expression, stably confluent 
monolayers of LMVECs grown in 96-well clusters were treated with NOS inhibitor 1 mM L-
NNA 1h before or PKG activator 20 ǍM 8-Br-cGMP (Calbiochem, CA) 10 min before 
fixation. Monolayers fixed with 4% paraformaldehyde were permeabilized with 0.2 % triton 
X-100 in PBS for 2 min, blocked with Chemicon® blocking reagent by 30 min incubation, 
and then incubated with rabbit anti-pSer1177-NOS primary antibody (Santa Cruz) overnight 
at 4C. The cells were counter-labeled with an antirabbit fluorescein (FITC)-tagged secondary 
antibody (Sigma, MO). The fluorescence was read with a Victor 1420 multilabel counter 
with a fluorescein setting (ǌex/em 485/535 nm). Both L-NNA and 8-Br-cGMP significantly* 
decreased fluorescence produced by the presence of fluorescein-tagged serine 1177 
phosphorylation of NOS (p<0.01 in both). Figure is a representative of two studies. Insert, B, 
shows similar results of cGMP decreasing serine 1177 phosphorylated NOS expression in 
western blots. 
The process of regulation of NOS after production of nitric oxide is not yet delineated61, 62, 63, 
,42 and may be governed by subcellular translocation involving the Golgi network.64,65, 66, 67 
The nucleus has not been considered as playing a prominent role in the metabolism of NOS. 
We localized serine-116- phosphorylated NOS (pSer116-NOS) in distinct vesicles in the cell 
nuclei as well as in the endoplasmic reticulum. At both sites, we found pSer116-NOS 
colocalized with protein kinase G1. Thus, PKG appears to be directly involved in 
inactivation of NOS after NO production and to be chaperoned with spent NOS.  
7. The implication of increased intracellular serine116-NOS detection after 
exogenous cGMP administration to cultured cells  
Both in-cell fluorescence and Western blots detections suggest that serine-116-
phosphorylated NOS is normally found in the endothelial cells and can be increased by 
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exogenous cGMP administration (Figures 15 and 16). It appears that there is a basal 
mechanism of removal of this phosphorylated NOS and administration of excess cGMP 
overwhelms this mechanism causing an accumulation. The mechanism does not seem to be 
by destruction of the serine-116 terminal (FACS analysis) but may be by internalization and 
translocation in subcellular compartments. Vesicles are implicated as the use of filipin, 
which disrupts lipid membranes, disturbed the effects of cGMP on NOS (Figure 17).32 
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Fig. 15.40 PKG activation increases anti-serine116-NOS antibody labeling of NOS N-terminal 
fractions in normal endothelial cells. LMVECs from a single suspension were equally seeded 
in 100mm diameter dishes. Five-day-confluent triplicate monolayers were used for controls 
and identical triplicate monolayers of sibling cells were used as tests treated with 300 nM 8-
Br-cGMP (Calbiochem, CA) for 15 min before routine immunoblot analysis. After 
electrophoresis and transfer of proteins to a membrane, the membrane was blocked with 5% 
non-fat milk and then incubated with a primary antibody against phosphorylated serine-116 
region of NOS (1: 200 concentration, Sigma, St. Louis) at 4C for 24h with gentle rocking. 
Protein bands were visualized by horseradish peroxidase conjugated secondary antibodies 
(Amersham, Buckinghamshire, UK) using Super Signal® West Pico Chemiluminescent 
Substrate kit (Pierce, Rockford, IL) to prepare the developing solution. Membranes were 
exposed to Blue Lite Autorad Films (ISC BioExpress, Kaysville, UT), and the films were 
processed in a HOPE developer. The film developed from western blotting showed that 
serine-116 phosphorylated NOS can be normally found in control cells as enzyme fragments 
and that these fragments are increased by PKG activation. 
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Fig. 16.32 Protein kinase G (PKG) activation decreases immunofluorescence of nitric oxide 
synthase (NOS) and increases that of the serine 116 phosphorylated analogue, pSer116-NOS, 
in lung microvascular endothelial cells (LMVECs). A: The PKG-modulating drugs were 
incubated with cells 30 min before fixation. Cells were processed using routine fluorescence 
immunohistochemistry with specific primary antibodies and species corresponding 
secondary antibodies. Left upper panels show that eNOS in control cells is found in the 
plasmalemma and cytosol as green Alexa 488-tagged NOS and also in the nucleus as red 
cy3-tagged NOS; the lower panels show that both 170 micromol/L diethylenetriamine 
NONOate (DETANONOate) and 3 micromol/L 8-Br-cGMP decrease NOS-cy3 expression. 
Right upper panels show that pSer116-NOS in control cells is found in the cytosol as green 
Alexa 488-tagged pSer116-NOS and also in the nucleus as red cy3-tagged NOS; the lower 
panels show that both 170 micromol/L DETANONOate and 3 micromol/L 8-Br-cGMP 
increased pSer116-NOS-cy3 expression in the cytosol and nucleus. Figures are 
representative of two experiments. B: The graph shows quantitative modification of serine 
116 immunofluorescence by 8-Br-cGMP. Stably confluent monolayers of LMVEC (n = 3) 
were treated with the PKG activator 20 micro mol/L 8-Br-cGMP with/without 20 
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micromol/L PKG inhibitor Rp-phenyl-1,N2-etheno-8-bromoguanosine-3’,5’-cyclic 
monophosphorothionate (Rp-8-bromo-PET-cGMPS) 10 min before fixation with 4% 
paraformaldehyde. The inhibitors were given 1 h before the activator. Fluorescence 
immunohistochemistry was performed with fluorescein-tagged secondary antibody. The 
fluorescence was read with a Victor 1420 multilabel counter (Perkin-Elmer, Waltham, MA, 
USA) with a fluorescein setting (ex/em 485/535 nm). Fluorescence intensity was increased 
by 8-Br-cGMP (p < 0.05) and the effect was attenuated by Rp-8-Br-PET-cGMPS (p < 0.05). 
The figure is a representative of two experiments. 
 
Fig. 17.32 Lipid vesicles are involved in protein kinase G (PKG) interaction with nitric oxide 
synthase (NOS). Confluent monolayers were treated with cholesterol extractor 2 
micromol/L cyclodextrin (CD) for 2 h to disrupt lipid vesicles and then incubated with 
various concentrations of 8-Br-cGMP and a combination of 0.5 micromol/L DAF-FM and 
cell-permeable 0.8 micromol/L DAF-FM diacetate, plus 4 microg/mL calcium ionophore to 
stimulate nitric oxide (NO) production. Nitric oxide produced was measured after 15 min of 
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incubation with DAF. Control cells were similarly treated with the exclusion of only CD. (A) 
Cell medium NO measurements from cells treated with CD showed greater NO production. 
In the absence of CD, 8-Br-cGMP caused a decrease in NO production. Cells with disrupted 
lipid lacked 8-Br-cGMP-inhibition of NOS. (B) Cell lysate NO measurements increased for 
various concentrations of 8-Br-cGMP in cells treated with CD compared with cells not 
treated with CD. Lipid disruption with CD raised NO production significantly (p < 0.01 for 
each 8-Br-cGMP concentration; n = 6). The effect of lipid disruption diminished with 
increasing concentrations of 8-Br-cGMP. (C) Time-course of the effect of CD on basal NO 
production. Cells were used in groups of 12 wells each for various controls and tests. All test 
groups were pretreated before adding DAF with 100 mmol/L PKG activator guanosine-3’-
5’-cyclic monophosphonate--phenyl-1NF-ethano-8-Br Na salt (8-Br-cGMP-PEB; 10 min 
before) without or with 20 mmol/L CD (given 2 h before) or with CD alone. Controls were 
included. Using paired t-tests, the differences at the 270 min time-point between both the 
controls and 8-Br-cGMP-PEB groups and the controls and CD groups were significant at p < 
0.05.  
8. Hypothetical comparison of the negative regulatory roles of caveolin-1 and 
PKG on endothelial NOS - a review of literature.  
Figure 18 and Table 1 compare the role of the well-studied caveolin-1 and the emerging role 
of PKG in inhibiting NOS. Both are endogenous components of cellular function under 
physiologic conditions. Caveolin-1 has been known as a negative regulator of NOS for many 
years but there is lack of significant clinical usage derived from this in terms of drug and 
molecular targeting and endogenous NO regulation. The suggested feedback role of PKG in 
the NOS metabolic cycle needs further studies for possible clinical applications. One aspect 
may be to target the N-terminal moiety (serine 116 region) that might be involve in 
transcription and de novo synthesis of NOS enzyme. This may be manipulated for utilization 
in vascular, neuronal, and other functional disorders involving NO. 
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Fig. 18. Hypothetical schema of differential subcellular co-localization of caveolin-1 or 
PKG1beta as inhibitors of NOS in endothelial cells. Caveolin-1 co-localizes with and is 
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known to inhibit nascent NOS produced in the Golgi or supplied to the plasma membrane 
for extracellular signals. The figure depicts caveolin-1 bound to NOS in the Golgi network 
and plasmalemma as Figure 13 indicates and as previous workers have shown.67, 68, 69, 62, 63 ,64 
The figure also depicts that PKG inhibits NOS after it is activated in the cytosol and is 
involved in the recycling of spent NOS as Figure 2 indicates. By some mechanism PKG 
colocalizes with NOS or with a NOS fragment in the nuclear region. Key: N = free nitric 
oxide synthase; C-N = hypothetical caveolin-1-NOS complex; PKG-N = hypothetical protein 
kinase G-NOS complex. 
 
 
 
 
 
COMPARISON CAVEOLIN-1 PKG 
Molecular effect on NOS post-translational 
inhibition62, 63, 52  
post activity inhibition32, 38 
Speculation on the form 
of NOS affected 
nascent (membrane bound) 
NOS64, 65, 66 
active NOS after NO production, or 
spent NOS 39, 40, 41  
 
Subcellular co-
localization with NOS 
plasma membrane, 
caveolae, golgi50, 67, 68, 69 
Cytosol, nucleus, endoplasmic 
reticulum32, 41 
Biological result makes NOS available for 
extracellular signals49, 52, 56, 
43, 68 
pro-translocation phosphorylation for 
enzyme degradation and recycling32, 
40, 41 
Activators calcium-calmodulin 53,68, 70, 
71 
albumin72, 73 
membrane lipid 
disruption72, 32  
bradykinin, acetyl choline66 
cGMP analogues38, 39 
 
Effect of activators increased NO production72, 
73 
decreased NO production32, 38, 39 
Inhibitors hypoxia 72, 74 cGMP analogues38, 39 
 
Effect of inhibitors decreased NO production72 increased NO production38, 39 
 
 
Table 1. Comparison of the negative regulatory roles of constitutive caveolin-1 and 
constitutive PKG on nitric oxide synthase in the endothelium. 
Protein Kinase G inhibits activated NOS by a feedback mechanism. Its actions appear to 
involve phosphorylation changes as well as molecular changes on the NOS molecule (Figure 
19) that determine the fate of the spent enzyme. The spent enzyme, from pictorial 
indications, appears to enter a vesicular system possibly as a degraded N-terminal form. The 
role of this cycle and the therapeutic possibilities linked to it are yet to be expanded.  
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Fig. 19. A hypothetical depiction of molecular and phosphorylation effects of PKG on NOS. 
9. Conclusions 
 Protein kinase G isoforms are normally found in endothelial cells 
 NO signaling activates guanylate cyclase and leads to activation of PKG in endothelial 
cells 
 PKG activation via NO-GC-cGMP signaling in endothelial cells appears to exert a 
feedback on active NOS. 
 Serine116-phosphorylated NOS appears to be spent NOS and to be chaperoned with 
PKG 1beta 
 Serine116-phosphorylated NOS moiety enters a vesicular system including the nucleus. 
 Serine116-phosphorylated NOS moiety may be an important messenger for 
replenishing the cell with nascent NOS enzyme. 
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